Stryker Corporation $SYK Stock: Norris Perne & French LLP MI Grows Stake

Norris Perne & French LLP MI raised its position in Stryker Corporation (NYSE:SYK) by 251.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 49,558 shares of the medical technology company’s stock after purchasing an additional 35,439 shares during the period. Norris Perne & French LLP MI’s holdings in Stryker were worth $13,648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. acquired a new stake in shares of Stryker during the second quarter worth $25,000. Kilter Group LLC bought a new stake in shares of Stryker in the second quarter valued at about $25,000. Cornerstone Financial Management LLC boosted its position in shares of Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after acquiring an additional 31 shares during the period. Highland Investment Advisors LLC acquired a new position in shares of Stryker in the second quarter valued at about $25,000. Finally, Compass Financial Management LLC acquired a new position in shares of Stryker in the second quarter valued at about $27,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Evercore set a $350.00 price target on shares of Stryker in a research report on Monday, July 6th. Piper Sandler cut their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. TD Cowen lowered their target price on shares of Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a report on Tuesday, September 22nd. Finally, Stifel Nicolaus dropped their price target on shares of Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a research report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $369.00.

Stryker Stock Performance

NYSE:SYK opened at $307.65 on Friday. The company has a market cap of $118.01 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 1.98 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a fifty day moving average price of $295.23 and a 200-day moving average price of $311.93.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. Stryker’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Insiders Place Their Bets

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.